

**Minutes of the meeting of the AREA PRESCRIBING COMMITTEE held on
Wednesday, 10th May 2023 via MS Teams**

MEMBERS:

Chris Lawson (Chair)	Head of Medicines Optimisation (SYICB, Barnsley)
Professor Adewale Adebajo	Associate Medical Director (Medicines Optimisation) on behalf of the Medical Director (BHNFT)
Tom Bisset	Community Pharmacist (LPC)
Dr Mehrban Ghani	Chair, Barnsley Healthcare Federation CIC, representing the Primary Care Networks (PCNs)
Dr Kapil Kapur	Consultant Gastroenterologist (BHNFT)
Dr Jeroen Maters	General Practitioner (LMC)
Dr Abdul Munzar	General Practitioner (LMC)
Mark Payne	Lead Pharmacist (SWYPFT)

IN ATTENDANCE:

Nicola Brazier	Administration Officer (SYICB, Barnsley)
Deborah Cooke	Lead Pharmacist (SYICB, Barnsley)
Joanne Howlett	Medicines Management Pharmacist (SY ICB, Barnsley)
Gillian Turrell	Lead Pharmacist (BHNFT)
Tsz Hin Wong	Senior Interface Pharmacist (BHNFT)

APOLOGIES:

Dr Madhavi Guntamukkala	Medical Director (SYICB, Barnsley)
Dr Munsif Mufalil	General Practitioner (LMC)

**ACTION
BY**

APC 23/78 QUORACY
The meeting was quorate.

APC 23/79 DECLARATIONS OF INTEREST RELEVANT TO THE AGENDA
The Chair invited declarations of interest relevant to the meeting agenda. The Head of Medicines Optimisation declared that she currently signs a variety of rebate agreements on behalf of the South Yorkshire ICB (Barnsley), none of which were applicable to today's agenda, noting that there is no personal financial gain and all savings from rebate schemes are re-invested into other local health services. The rebates are all in line with the recommended PrescQIPP guidance and the full list is available on the website. There were no further declarations of interest to note.

APC 23/80 DRAFT MINUTES OF THE MEETING HELD ON 12th APRIL 2023
Page 4, spelling of ClinOptic® to be corrected.

Subject to the correct spelling of ClinOptic®, the minutes were accepted as an accurate record of the meeting.

Referring to the issues raised at the last meeting regarding QIPP and stock availability, the Lead Pharmacist (SYICB, Barnsley) advised that a work plan was being pulled together and that the Community Pharmacist would be kept involved in terms of the dates and awareness, ensuring communication of any issues prior to going 'live'

with work, and ensuring that community pharmacists are made aware of planned changes in good time.

The Lead Pharmacist (SYICB, Barnsley) advised that in light of issues raised by the Community Pharmacist at the last meeting regarding stock at the wholesalers, assurance is being obtained to ensure that stocks are in the wholesalers before we add the brand to the formulary or add switches on ScriptSwitch.

APC 23/81
23/81.1

MATTERS ARISING AND APC ACTION PLAN

NICE TAs (February 2023)

The Lead Pharmacist, BHNFT advised that the following NICE TA **was** applicable for use at BHNFT: -

- TA872 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

The Lead Pharmacist, BHNFT advised that the following NICE TA **was not** applicable for use at BHNFT: -

- TA863 Somatrogen for treating growth disturbance in people 3 years and over

23/81.2

NICE TAs (March 2023)

The Lead Pharmacist, BHNFT advised that the following NICE TA **was** applicable for use at BHNFT: -

- TA874 Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma

The Lead Pharmacist, BHNFT advised that the following NICE TA **was not** applicable for use at BHNFT: -

- TA873 Cannabidiol for treating seizures caused by tuberous sclerosis complex

The Lead Pharmacist, BHNFT **to advise** if the following NICE TAs are applicable for use at BHNFT: -

- TA875 Semaglutide for managing overweight and obesity
- TA877 Finerenone for treating chronic kidney disease in type 2 diabetes

GT

23/81.3

Action Plan – other

Combination anticoagulant and antiplatelet treatment for patients with concomitant AF and ACS Guideline

The Lead Pharmacist, BHNFT to advise a revised target date, documenting reason for deferral.

GT

23/81.4

Lurasidone

The Lead Pharmacist, SWYPFT advised that the completion of a new product application was in progress and sought clarification that it was required.

It was noted that if initiated in another area but managed by SWYPFT services, that other area classifications were respected and therefore covered by our processes, however if SWYPFT mental health clinicians are initiating lurasidone, a new product application and updated shared care guidance to include it was required as primary

care do not currently have guidance to support its prescribing. This action would be progressed.

Agreed action: -

- The new product application and updated shared care guideline to be presented together for consideration by the Committee.

MT

23/81.5

Target dates

Empagliflozin for chronic heart failure with reduced ejection fraction

Amber-G Guidance

It was planned to take this to the June LMC and APC meetings.

GT

Ticagrelor Audit

It was agreed that a summary of the ticagrelor audit findings would be brought to the next meeting, where timescales for a way forward or re-audit would be agreed, noting that patients are being compromised due to unclear communication around length of treatment.

GT

Entresto® Pathway

The Lead Pharmacist, BHNFT noted that this had not been progressed due to difficulty liaising with the heart failure nurses, however advised that no issues have been raised with the amber classification. In agreement with the Lead Pharmacist, SWYPFT, it was agreed to remove this action from the action plan. The service lead would be contacted to advise that due to no engagement from the service, Entresto® would remain classified amber and this action would be removed from the action plan. This could be brought back to the Committee if the service wishes to request the change in classification again.

Agreed action: -

- The Lead Pharmacist, SWYPFT to advise the service lead of this decision.

MP

The Lead Pharmacist, BHNFT to review the action plan target dates for June 2023 and advise of any revision to those dates, providing a reason for deferral.

GT

APC 23/82

SHARED CARE GUIDELINES/AMBER G SHARED CARE GUIDELINES

23/82.1

Shared Care Protocol for Myasthenia Gravis or Chronic Inflammatory Demyelinating Polyradiculopathy in Adults (updated)

The Head of Medicines Optimisation advised that the draft guidelines, presented at the November 2021 APC meeting have now been formally agreed across all South Yorkshire areas. There were no amendments to note following the November 2021 APC meeting and therefore the Committee endorsed the Shared Care Protocol for Myasthenia Gravis or Chronic Inflammatory Demyelinating Polyradiculopathy in Adults.

A link to the shared care protocol would be published on the BEST website.

APC 23/83

FORMULARY REVIEWS

23/83.1

Formulary Review Plan

There were no changes to note.

APC 23/84 NEW PRODUCT APPLICATION LOG

The new product application log was received for information with no changes to note.

APC 23/85 REGIONAL MEDICINES OPTIMISATION COMMITTEE (RMOC) & SOUTH YORKSHIRE INTEGRATED MEDICINES OPTIMISATION COMMITTEE (SY IMOC)

23/85.1 SYICB IMOC Draft Minutes, 5th April 2023

The minutes were shared for information.

23/85.2 SYICB IMOC Ratified Minutes, 1st March 2023

The minutes were shared for information.

23/85.3 SYICB IMOC – Verbal key points - 3rd May 2023

Areas discussed at the May 2023 meeting included the terms of reference, focussing on traffic light classification. It was noted that IMOC would not undertake any decisions around formulary status, and that those decisions would be made at Place. However, there were discussions around moving into pathways and recommendations around formulary which will have an impact at Place, therefore when minutes from the May 2023 IMOC meeting are presented at the next APC meeting, more attention needed to be given to how we want to manage those decisions that have been made. An example was given around the classification of Ogluo® (Glucagon) and the development of a pathway.

Reference was made to the South Yorkshire Gluten Free Prescribing Guidelines which have been shared and endorsed by this Committee.

GP representation at the IMOC was discussed and there was an offer made to GP representatives at yesterday's LMC meeting, noting that Dr Bannon will receive papers to widen/increase GP engagement with IMOC.

A working group has been set up, looking at how we manage out of area requests, noting that currently we respect shared care guidelines from other areas, whereas one of our localities only accepts their shared care guidelines. The working group is looking to resolve this issue.

Work being undertaken by IMOC is looking extremely positive in terms of moving forward, with potential to reduce some of the workload of the APC. It was clarified that this Committee will always be required in terms of implementation and making sure we meet the needs of the prescribers, providing the advice and support needed.

23/85.4 Agreed Traffic Light Criteria

The IMOC have developed and agreed a process to work through the criteria to harmonise the traffic light lists across South Yorkshire ICB. It was noted that this is very similar to the Barnsley criteria with some possible nuances with amber shared care.

23/85.5 IMOC Traffic Light Drugs List

The traffic light list of drugs that have been classified by IMOC was shared, noting nothing yet that we have felt is a particular challenge.

23/85.6

IMOC Process for creating new and updating current shared care protocols and prescribing guidelines

The agreed IMOC process was shared, noting that the IMOC wish to be informed when undertaking any work on shared care protocols and prescribing guidelines at Place to check if this is something they want to take forward and collaborate with across South Yorkshire. This will create another stage in a process which may bring extended timeframes to work being completed if collaborating across the wider area.

23/85.7

Templates:

- Shared care proformas and protocols
- SY IMOC form for supporting information to accompany proposals for prescribing guidelines and shared care protocols
- SY IMOC medicines traffic light drug list application form

The endorsed templates were received and noted for information.

The Head of Medicines Optimisation clarified that from an APC perspective and for Barnsley prescribers, and anyone wanting to make an application, it was important to maintain the current Barnsley process, noting that the MMT would undertake the completion of any additional/necessary paperwork and engagement with the IMOC.

Secondary care colleagues were keen to maintain the current process and were therefore in support with what was being proposed.

APC 23/86

23/86.1

BARNSELY APC REPORTING

APC Reporting March 2023

The Lead Pharmacist, (SY ICB, Barnsley) presented the enclosure showing reports received directly into the APC reporting mailbox. It was noted that there has been an increase in the number of reports in March compared to previous months but sharing that the same increase was seen in March 2022. There were 103 APC reports received for the month of March 2023.

23/86.2

APC Reporting March 2023 Key Themes

The summary report was presented, showing 103 reports in total, including 55 received directly into the APC reporting mailbox and 48 interface queries received directly to the BHNFT pharmacy team for the month of March 2023.

From the category breakdown, the largest key theme this month is D1 communication as highlighted in previous meetings, plus reports relating to other themes including medication supply issues, formulary related reports, other hospital communication, and summary care record related reports.

Details relating to some of the significant issues from APC reports (D1 communication/other discharge related, other hospital communication, formulary or guideline related, prescribing error, and other) were shared and highlighted.

Feedback from some MMT team members was shared regarding concern expressed that there are sometimes delays encountered in receiving answers to queries from BHNFT pharmacy team, including

urgent queries. The work that BHNFT pharmacy team are doing was appreciated and the capacity issues acknowledged.

Referring to reports of multiple practices not receiving blood test results, the Chair, Barnsley Healthcare Federation CIC, representing the Primary Care Networks (PCNs) advised that this issue has been discussed in various forums and is a high priority to monitor and resolve the issue. The APC reporting spreadsheet would be updated to record this update.

DC

In relation to the duplicate/multiple D1 issue, it was noted that a request has been made through the BHNFT D1 Issues Group to obtain information on the number of D1s issued and Andrew Wiles has advised that a report can be produced to analyse the volume from BHNFT end.

It was fed back that meetings have been held around sharing of access to BHNFT IT systems and work around this is progressing.

The Community Pharmacist referred to BAPC23/03/10 (NOMAD trays), clarifying that there are no circumstances in which a pharmacy is required to supply a NOMAD to any patient. The APC reporting spreadsheet would be updated to record these comments in the summary findings.

DC

It was noted that an Oxygen Steering Group has been established at BHNFT, who are reviewing the issues reported by Laura Gill, Senior Respiratory Nurse, BREATHE Service (SWYPFT). The Lead Pharmacist, BHNFT was awaiting feedback from that group.

23/86.3

APC Reporting March 2023 Interface Issues

The enclosure detailing the interface queries received directly within BHNFT pharmacy team was received and noted.

APC 23/87

NEW NICE TECHNOLOGY APPRAISALS (APRIL 2023)

23/87.1

NICE TAs April 2023

The Lead Pharmacist, BHNFT advised that the following NICE TA **was** applicable for use at BHNFT: -

- TA878 (Update) Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

The Lead Pharmacist, BHNFT advised that the following NICE HSTs/TAs **were not** applicable for use at BHNFT: -

- HST24 (Partial Review of HST15) Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy
- HST15 (Update) Onasemnogene abeparvovec for treating spinal muscular atrophy
- TA879 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment

The Lead Pharmacist, BHNFT **to advise** if the following NICE HSTs/TAs are applicable for use at BHNFT: -

- HST25 Lumasiran for treating primary hyperoxaluria type 1

GT

- HST26 Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency
- TA880 Tezepelumab for treating severe asthma

23/87.2 Feedback from BHNFT Clinical Guidelines and Policy Group
There was nothing relevant to report.

23/87.3 Feedback from SWYPFT NICE Group
There was nothing relevant to report.

APC 23/88 FEEDBACK FROM THE MEDICINES MANAGEMENT GROUPS

23/88.1 Primary Care Quality & Cost-Effective Prescribing Group (QCEPG)

The Head of Medicines Optimisation advised that the focus of discussion at the last meeting was around the growth seen in primary care prescribing in the last year which is posing a significant challenge. There were many reasons driving the increase in prescribing costs.

23/88.2 BHNFT
There was nothing relevant to report.

23/88.3 SWYPFT Drug and Therapeutics Committee
There was nothing relevant to report.

23/88.4 Community Pharmacy Feedback
The recently published Community Pharmacy Contractual Framework delivery plan was referenced, noting that time was required to understand the detail.

Awareness was raised to the changes to COVID prescribing. The supply of COVID medicines through primary care would be added to next month's agenda.

NB

The Committee were made aware that from mid-July, the government have imposed some changes on community pharmacy regulations and one of those allows pharmacies to change their opening hours, noting that locally this could impact with a reduction in opening hours, anticipating that pharmacies on 100 hours (28 across South Yorkshire) may take the opportunity to reduce their hours. This process opens on 25th May 2023. It was noted that change of hours is usually communicated to the LPC and the LMC and updated on the NHS Choices website as well as individual pharmacy websites.

The Head of Medicines Optimisation proposed we look at this over Barnsley place to get some understanding/engagement with pharmacies, particularly about the Specialist Drugs stockist scheme etc.

CL

23/88.5 Wound Care Advisory Group
There has been no meeting, however it was reported that a programme of work is being taken forward and work is being progressed around wound care training and development.

APC 23/89 ISSUES FOR ESCALATION TO THE BARNSELY PLACE QUALITY & SAFETY COMMITTEE

The Head of Medicines Optimisation advised that a template has been issued to produce a report after each APC meeting that will feed into the Integrated Place Based Partnership Quality Group. These reports would be shared at future APC meetings for awareness of what has been reported.

The key issues to escalate this month are APC reporting, IMOC and the collaborative working.

CL

Agreed action: -

- A copy of the report escalating issues to the Quality Group to be brought back to the next APC meeting.

CL

APC 23/90 FORMULARY ACTIONS

23/90.1

IMOC Traffic Light Drugs List – April 2023

The Medicines Management Pharmacist advised the Committee of the following changes needing to be made to the Barnsley formulary: -

- IQoro device (currently non-formulary) – change to non-formulary grey.
- Efmody® Hydrocortisone MR 5mg & 10mg capsules (currently non-formulary provisional grey) – change to formulary red with IMOC looking to produce a shared care protocol, moving to formulary amber when shared care protocol produced.

The Committee were advised that it was being suggested that where the traffic light status is agreed by the IMOC, that these drugs will be removed from the Barnsley traffic light list when added to the IMOC traffic light list, working towards having one traffic light list at some point in the future. A link to the IMOC traffic light list would be included at the top of the Barnsley traffic light list and on the formulary, but that the Barnsley traffic light list would need to be used in conjunction with the IMOC traffic light list. This was in line with other Places across South Yorkshire.

The Head of Medicines Optimisation raised some concerns with prescribers needing to refer to both traffic light lists and agreed to discuss this at the next LMC meeting to see what best supports prescribers.

The Lead Pharmacist (SY ICB, Barnsley) advised that following discussions how best to manage this going forward, it had been concluded that prescribers were generally more inclined to refer to the formulary or use ScriptSwitch, which will remain up to date. She would encourage to simplify the process, that the formulary be used as the central reference point to check the traffic light classification and formulary status.

Agreed action: -

- The Head of Medicines Optimisation to discuss what best supports prescribers at the next LMC meeting.

CL

23/90.2 SPS New Medicines Newsletter March 2023
Received for information.

23/90.3 Horizon Scanning May 2023
The Medicines Management Pharmacist presented the document that was discussed at the May 2023 IMOC meeting. The IMOC assigned the following classifications to the products listed in the March 2023 SPS newsletter (including new indications, licences changes and new formulations) as below: -

- Covid-19 vaccine (VidPrevtyl Beta®) 10 dose multi-dose vial (new Medicine) – green
- Elasmomeran + davesomeran (Spikevax® bivalent Original/Omicron BA.4-5) Single dose and 5 dose multi-dose vials (new booster formulation of Spikevax® - green

Due to capacity at the May 2023 IMOC meeting, the remaining products listed in the March 2023 SPS newsletter would be discussed at the June 2023 IMOC meeting and brought back to the June 2023 APC meeting.

JH

The Committee endorsed the classifications assigned by IMOC.

APC 23/91 **MHRA DRUG SAFETY UPDATE (APRIL 2023)**
The update was noted with the following information highlighted: -
Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions
Healthcare professionals prescribing nitrofurantoin should be alert to the risks of pulmonary and hepatic adverse drug reactions and advise patients to be vigilant for the signs and symptoms in need of further investigation.

Agreed action: -

- A reminder of the risks to be included in the next MMT newsletter and the BHNFT MM bulletin.

JH
GT

APC 23/92 **SOUTH YORKSHIRE AREA PRESCRIBING COMMITTEE MINUTES (FOR INFORMATION)**
The minutes from NHS South Yorkshire ICB Sheffield (16th March 2023) and NHS South Yorkshire ICB Doncaster & Bassetlaw (31st March 2023) were received and noted.

APC 23/93 **ANY OTHER BUSINESS**
23/93.1 Pastures New
The Committee were advised that this would be the Lead Pharmacists (SWYPFT) last meeting as he would be leaving post at the end of May 2023.

The Head of Medicines Optimisation said it had been a joy working with him and he would be missed, thanking him for his useful contribution to this meeting, and many other meetings.

23/93.2

Class 1 MHRA National Patient Safety Alert

The Lead Pharmacist, BHNFT referred to the class 1 alert, issued 9th May 2023 regarding the recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure. BHNFT have identified and contacted all patients supplied in the last 12 months, noting that patients may be contacting GPs for prescriptions for replacements. It was agreed that this information (NHS number and registered GP practice) would be shared with the Lead Pharmacist (SY ICB, Barnsley) to share with practices.

The Lead Pharmacist, (SY ICB, Barnsley) confirmed that information had been sent to the MMT today with an ask to support practices with the required actions. The additional information received from BHNFT would be shared with practices.

Agreed action: -

- The Lead Pharmacist, BHNFT to share patient details to support GP practices with the required action.

GT/DC

APC 23/94

DATE AND TIME OF THE NEXT MEETING

The time and date of the next meeting was confirmed as Wednesday, 14th June 2023 at 12.30 pm via MS Teams.

ADOPTED